EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A

Akifumi Kato iD, Asami Toshima, Gennosuke Takekawa, Hikaru Miyagi, Ai Kubota, Sayaka Hori, Yasunori Uemura, Rinpei Niwa

Protein Science · 2025

DOI: 10.1002/pro.70351 ↗

At a glance

Journal article in Protein Science, 2025. Written by Akifumi Kato and 7 co-authors. Institution: Innovation Center, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. Major MEDLINE topics: Receptors, Fc, Histocompatibility Antigens Class I, Immunoglobulin G, Protein Engineering. 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs) have transformed therapeutic strategies for various diseases. However, administering them can lead to unwanted adverse effects and insufficient delivery to local disease sites. Recent research has shown that substitutions in the immunoglobulin G (IgG) Fc region, designed to eliminate binding to the neonatal Fc receptor (FcRn), which accelerates clearance from systemic circulation, may improve the safety of antibody therapies intended for localized use. A major concern with these substitutions is their ability to impair binding to protein A, which is considered the gold standard for large‐scale antibody purification. In this study, we investigated multiple amino acid substitutions at residues I253, H310, H435, and Y436—positions known to affect FcRn or protein A interactions—and found that H435F eliminates FcRn binding while maintaining protein A affinity. Importantly, the H435F substitution resulted in accelerated clearance and a shorter serum half‐life in human FcRn transgenic mice. Moreover, purification using protein A chromatography proved to be effective without significantly compromising yield. Overall, these findings highlight the potential of the H435F substitution to optimize the pharmacokinetics of antibody therapeutics for localized use, reducing systemic side effects. This study paves the way for the use of antibody‐based therapeutics in localized treatments.

Subjects

MeSH terms (MEDLINE)

Receptors, FcHistocompatibility Antigens Class IImmunoglobulin GProtein EngineeringStaphylococcal Protein AImmunoglobulin Fc FragmentsAnimalsHumansMiceMice, TransgenicAmino Acid SubstitutionProtein Binding

Author keywords

IgGantibody engineeringlocalized therapyneonatal Fc receptorprotein ashorter serum half‐life

Substances

Receptors, FcFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GStaphylococcal Protein AImmunoglobulin Fc Fragments

Authors and institutions

  • Innovation Center, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.
  • Bio-Pharmaceutical Center, Research Division, Kyowa Kirin Co. Ltd, Shizuoka, Japan.
  • Bio-Pharmaceutical Center, Research Division, Kyowa Kirin Co. Ltd, Tokyo, Japan.
  • Intellectual Property Department, Kyowa Kirin Co., Ltd, Tokyo, Japan.
  • Research Planning Department, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.

ORCID profiles: Akifumi Kato

Cite

APA

Kato, A., Toshima, A., Takekawa, G., Miyagi, H., Kubota, A., Hori, S., Uemura, Y., & Niwa, R. (2025). Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. Protein Science. https://doi.org/10.1002/pro.70351

Vancouver

Kato A, Toshima A, Takekawa G, Miyagi H, Kubota A, Hori S, et al. Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. Protein Science. 2025. doi:10.1002/pro.70351

BibTeX
@article{Kato2025,
  author = {Kato, Akifumi and Toshima, Asami and Takekawa, Gennosuke and Miyagi, Hikaru and Kubota, Ai and Hori, Sayaka and Uemura, Yasunori and Niwa, Rinpei},
  title = {Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A},
  journal = {Protein Science},
  year = {2025},
  doi = {10.1002/pro.70351}
}
Start for free →